Life After GLP-1: Maintenance Dosing, Microdosing, Tapering & What Happens When You Stop (2026 Decision Hub)

Reaching your goal weight on a GLP-1 is the start of a new question, not the end. The published evidence (STEP-4 JAMA 2021 PMID 33755728; SURMOUNT-4 JAMA 2024 PMID 38078870; Wilding 2022 Diabetes Obes Metab PMID 35315183) consistently shows that ~2/3 of weight is regained within 1 year of fully discontinuing semaglutide or tirzepatide. That puts most patients in one of four scenarios: stay on the maintenance dose indefinitely, space the same dose to every-other-week or every-3-week cadences, microdose at a fraction of the maintenance dose, or fully taper off and accept some regain. Each has distinct evidence, costs, and clinical considerations. This is the decision hub.

The baseline evidence: what happens when you stop

Three published trials anchor the “what happens after stopping” question:

• STEP-1 trial extension (Wilding et al., Diabetes Obes Metab 2022, PMID 35315183) — patients who had reached ~17% mean body-weight loss on semaglutide 2.4 mg over 68 weeks were withdrawn from the drug + the lifestyle intervention. By week 120 (roughly 1 year after discontinuation), they had regained roughly 2/3 of the lost weight.
• STEP-4 (Rubino et al., JAMA 2021, PMID 33755728) — patients on semaglutide 2.4 mg for 20 weeks were re-randomized to continue or switch to placebo. The continued-semaglutide arm lost an additional 7.9% over the next 48 weeks; the switched-to-placebo arm regained 6.9%.
• SURMOUNT-4 (Aronne et al., JAMA 2024, PMID 38078870) — same design for tirzepatide. Patients who continued tirzepatide for 88 weeks total maintained their weight loss; patients who switched to placebo at week 36 regained ~14% of body weight by week 88.

The take-home: GLP-1 weight loss is pharmacologically maintained, not biologically consolidated. Discontinuation predictably produces regain over months. The four maintenance scenarios below are ways to manage that biology.

Scenario 1 — Stay on the full maintenance dose

Who this fits: patients who tolerate the maintenance dose without persistent side effects, have insurance coverage that continues at maintenance, and want the highest probability of preventing regain.

Evidence: SURMOUNT-4 (88-week tirzepatide continuation) showed weight maintenance with continued therapy. STEP-4 (semaglutide continuation arm) showed continued weight loss, not just maintenance. The STEP-5 2-year follow-up extends the maintenance picture out further. This is the most evidence-backed scenario for keeping weight off.

Practical considerations:

• Insurance coverage: most plans require documented ≥5% baseline body-weight loss to renew the PA at month 12 (Wegovy/Zepbound/Foundayo per Cigna IP0206 + Aetna 4774-C/6947-C; Saxenda has a 4% threshold per Aetna 1227-C). Some plans add a stricter rule requiring the patient to maintain BMI above the original PA threshold — read your specific plan's reauth criteria. See our insurance appeal playbook for the BMI clawback pattern.
• Cost: $25/month with manufacturer copay savings card if commercially insured. NovoCare $299/month self-pay Wegovy. LillyDirect $299-$449/month Zepbound vials.
• Identity / body-image considerations: maintenance is also when patients commonly report identity grief, “ghost fat,” disclosure pressure, and relationship-role disruption — see our body dysmorphia + disclosure + post-loss grief guide for the published evidence (Sarwer, Mitchell, Plenn 2025 r/WegovyWeightLoss thematic analysis) and the practical framework.
• Long-term safety: the longest-published continuous GLP-1 exposure in trial data is the SELECT cardiovascular outcomes trial (semaglutide ~3.3-year median exposure in 17,604 patients) — no late-emerging safety signals beyond the known boxed warning + acute pancreatitis / gallbladder / ileus / kidney injury / retinopathy precautions.

Scenario 2 — Maintenance dose with extended spacing

Who this fits: patients who reached goal weight on the maintenance dose, want to reduce side effects or cost, and find the full weekly schedule unnecessary at their current weight set point.

Common spacing protocols (off-label, no FDA endorsement):

• Every-other-week dosing at the maintenance mg (e.g., Wegovy 2.4 mg every 14 days instead of every 7 days)
• Every-3-week dosing at the maintenance mg

Evidence: there is no published phase 3 trial evaluating every-other-week or every-3-week dosing of semaglutide 2.4 mg or tirzepatide for weight maintenance. The spacing protocols are extrapolated from the drug half-life: semaglutide elimination half-life is ~7 days, so a single 2.4 mg dose produces meaningful steady-state activity for 2-3 weeks before falling off. Tirzepatide half-life is ~5 days, so the spacing window is shorter.

Practical considerations:

• Safety: spacing the same dose is generally safer than reducing the per-injection dose because each injection still hits the same C-max — the patient experiences the same pharmacokinetic peak as the original weekly schedule.
• Cost reduction: a 28-day Wegovy pen lasts 8 weeks at every-other-week dosing instead of 4 weeks at weekly dosing. That halves the per-month cost.
• Risk of regain: some patients report weight creep on extended-spacing protocols that didn't occur on weekly dosing. Monitor weight monthly and tighten the spacing if regain begins.
• Insurance complications: a spaced dose may stretch the days-supply on the prescription — your pharmacy will calculate refills based on the prescribed schedule. If your prescriber writes the prescription as “2.4 mg subcutaneous every 14 days” the insurance may approve based on the longer days-supply but require justification at next refill.
• This is off-label. The FDA-approved label specifies once-weekly dosing for both Wegovy and Zepbound. Off-label spacing is a legal clinical decision but is not backed by phase 3 trial data — it's expert-opinion + pharmacokinetics-derived.

Scenario 3 — Microdosing at a fraction of the maintenance dose

Who this fits: patients who want continued appetite-suppression support at lower intensity, have access to compounded products that allow sub-label dose increments, or are price-sensitive.

Common microdose protocols:

• Compounded semaglutide at 0.25-1.0 mg weekly instead of 2.4 mg weekly (Wegovy maintenance dose) or compared to 2.0 mg weekly (Ozempic max diabetes dose)
• Compounded tirzepatide at 2.5-5 mg weekly instead of the 10-15 mg maintenance range

Evidence: microdosing has no published phase 3 trial endpoint specifically for “microdose maintenance”, but STEP-1 and SURMOUNT-1 dose-response data show clearly that lower doses produce smaller weight loss — and at maintenance (post-goal), some patients find that smaller weight-loss pressure is exactly what they want. See our deep dives: semaglutide microdosing evidence and tirzepatide microdosing evidence.

Practical considerations:

• Brand-name pens dose in fixed increments (Wegovy 0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg pens). Microdosing below 0.25 mg requires a compounded product or off-label use of a vial format with a syringe.
• Compounded products carry the regulatory uncertainty of post-grace-period 503A status. FDA enforcement discretion for compounded semaglutide ended February 2025; for compounded tirzepatide it ended October 2024.
• Insurance does not cover microdosing of brand-name products. Pre-filled pens fill at the labeled dose only; the patient may pay full cost to fill a pen and then use only fractional doses, which changes the per-mg economics.
• This is off-label. Same caveat as extended-spacing — legal clinical decision, no phase 3 backing for the specific microdose-maintenance protocol.

Scenario 4 — Full taper and discontinuation

Who this fits: patients who want to stop the drug entirely (cost, side effects, life circumstances, pregnancy planning), are willing to accept some weight regain, or have completed a defined treatment course agreed with their prescriber.

Evidence: the regain pattern is consistent across published extension data — STEP-1 extension showed ~2/3 regain at 1 year post-discontinuation; STEP-4 showed immediate regain in the placebo-switch arm; SURMOUNT-4 showed similar regain pattern with tirzepatide. Discontinuation does NOT mean total reversal — patients typically retain some net loss vs their pre-treatment baseline, but most or all of the GLP-1-attributable effect is reversible.

Practical taper protocol: see our taper guide for the dose-reduction sequence and the timing rationale. Briefly: rather than stopping cold turkey from the maintenance dose, prescribers commonly recommend stepping down through the previous dose tiers (e.g., Wegovy 2.4 → 1.7 → 1.0 → 0.5 → 0.25 → off, holding each step for 2-4 weeks) to ease the appetite-rebound transition. There is no FDA-mandated taper protocol; the staged taper is clinical custom and a hedge against the common pattern of rapid appetite return at sudden discontinuation.

What happens to weight: see our deep dive what happens when you stop semaglutide for the published trial data, the time course of regain, and the lifestyle interventions that reduce regain magnitude.

Quick decision tree

• Insurance covers maintenance + you tolerate the full dose → Stay on full maintenance (Scenario 1). Best evidence, lowest regain risk.
• Insurance covers maintenance but cost is still tight → Discuss every-other-week spacing with your prescriber (Scenario 2). Halves the per-month medication cost without changing the per-injection dose.
• Insurance dropped coverage at the BMI threshold → Cash-pay path with extended-spacing or microdosing (Scenario 2 or 3). See our cash-pay channel guide.
• You want to stop entirely (cost, pregnancy, life) → Staged taper per the taper guide. Expect some regain per the published trial data; pair with strict dietary + exercise interventions to minimize.
• You experienced significant side effects on full maintenance dose → Discuss microdosing protocol with your prescriber (Scenario 3). Compounded products enable fractional dosing that brand-name pens don't.
• You're just curious what your set point is off the drug → Time-limited withdrawal (e.g., 6 months) with the option to restart if regain is excessive. The drug remains effective if restarted; there is no documented loss of response from prior exposure.

Related deep dives

• What happens when you stop semaglutide — full trial data on regain magnitude, time course, appetite/food-noise rebound, and metabolic effects
• How to taper off GLP-1 safely — the staged taper protocol, dose-reduction sequence, timing rationale, and side-effect transitions
• Semaglutide microdosing evidence guide — fractional-dose protocols, the dose-response data, and the regulatory caveat for compounded fractional dosing
• Tirzepatide microdosing evidence guide — same framework adapted to tirzepatide
• Insurance dropped your GLP-1 — appeal playbook — for patients hit by the BMI clawback or CVS Caremark July 2025 swap
• Cash-pay coupon & channel guide — channel-by-channel cash-pay options if insurance coverage ends